Association among C-reactive protein, fatty liver disease, and cardiovascular risk

被引:29
作者
Lizardi-Cervera, Javier
Chavez-Tapia, Norberto C.
Perez-Bautista, Oliver
Ramos, Martha H.
Uribe, Misael
机构
[1] Med Sur Clin & Fdn, Dept Gastroenterol, Mexico City, DF, Mexico
[2] Med Sur Clin & Fdn, Dept Internal Med, Mexico City, DF, Mexico
关键词
non alcoholic fatty liver disease; C-reactive protein; metabolic syndrome; cardiovascular risk;
D O I
10.1007/s10620-006-9262-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is associated with several metabolic disturbances involving inflammation. Ultrasensitive C-reactive protein (uCRP), a marker of coronary heart disease and other chronic diseases, has not been investigated in NAFLD. We tested the relationship between uCRP and NAFLD in middle-aged asymptomatic subjects, independently of other metabolic disturbances associated with metabolic syndrome and cardiovascular risk. We compared 310 subjects with steatosis visible on ultrasound (cases) with 630 and without (controls). Body mass index (BMI), blood pressure and serum levels of uCRP, glucose, lipids, and lipoproteins were measured in all subjects. Differences between groups and the impact of serum uCRP levels were tested by univariate and multivariate logistic regression analysis. Cases were statistically different from controls in the frequency of metabolic syndrome (66.4% vs. 26.7%; P < 0.001). Cases were significantly older (P < 0.001), and had significantly higher values for BMI, glucose, total cholesterol and triglycerides (P < 0.001), and mean uCRP concentrations (4.5 vs. 2.79 mg/L; P < 0.001). By univariate analysis, variables significantly associated with cases were glucose (OR, 4.09; 95% CI, 2.98-5.61), BMI (OR 5.54; 95% CI, 4.09-7.49), and uCRP (OR 7.06; 95% CI, 4.51-11.02). By multivariate analysis, uCRP levels were associated with hepatic steatosis (OR 5.83; 95% CI, 3.07-11.06). Cardiovascular risk was also higher in subjects with NAFLD (4.7 vs. 2.8). Subjects with hepatic steatosis showed an increased concentration of uCRP independently of other metabolic disturbances; this suggests an increased risk of cardiovascular diseases and could be used as a marker of chronic inflammation.
引用
收藏
页码:2375 / 2379
页数:5
相关论文
共 38 条
[21]  
Méndez-Sánchez N, 2005, WORLD J GASTROENTERO, V11, P1737
[22]  
MONZON CG, 2001, GASTROENTEROL HEPATO, V24, P395
[23]   Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis [J].
Musso, G ;
Gambino, R ;
De Michieli, F ;
Cassader, M ;
Rizzetto, M ;
Durazzo, M ;
Fagà, E ;
Silli, B ;
Pagano, G .
HEPATOLOGY, 2003, 37 (04) :909-916
[24]   Periodontal infections contribute to elevated systemic C-reactive protein level [J].
Noack, B ;
Genco, RJ ;
Trevisan, M ;
Grossi, S ;
Zambon, JJ ;
De Nardin, E .
JOURNAL OF PERIODONTOLOGY, 2001, 72 (09) :1221-1227
[25]   Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men [J].
Park, SH ;
Kim, BI ;
Yun, JW ;
Kim, JW ;
Park, DI ;
Cho, YK ;
Sung, IK ;
Park, CY ;
Sohn, CI ;
Jeon, WK ;
Kim, H ;
Rhee, EJ ;
Lee, WY ;
Kim, SW .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (06) :694-698
[26]   Markers of inflammation and cardiovascular disease application to clinical and public health practice - A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association [J].
Pearson, TA ;
Mensah, GA ;
Alexander, RW ;
Anderson, JL ;
Cannon, RO ;
Criqui, M ;
Fadl, YY ;
Fortmann, SP ;
Hong, Y ;
Myers, GL ;
Rifai, N ;
Smith, SC ;
Taubert, K ;
Tracy, RP ;
Vinicor, F .
CIRCULATION, 2003, 107 (03) :499-511
[27]   Obesity, insulin resistance, and cardiovascular disease [J].
Reaven, G ;
Abbasi, F ;
McLaughlin, T .
RECENT PROGRESS IN HORMONE RESEARCH, VOL 59, 2004, 59 :207-223
[28]   Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? [J].
Ridker, PM ;
Wilson, PWF ;
Grundy, SM .
CIRCULATION, 2004, 109 (23) :2818-2825
[29]   Clinical application of C-reactive protein for cardiovascular disease detection and prevention [J].
Ridker, PM .
CIRCULATION, 2003, 107 (03) :363-369
[30]   High-sensitivity C-reactive protein: A useful marker for cardiovascular disease risk prediction and the metabolic syndrome [J].
Rifai, N .
CLINICAL CHEMISTRY, 2005, 51 (03) :504-505